Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor in Multiple Myeloma.

Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor in Multiple Myeloma.
复制标题

DOI:
10.3389/fonc.2021.785297
复制
发表时间:
2021
影响因子:
4.7
通讯作者:
Liu Z
Liu Z
中科院分区:
医学3区
文献类型:
--
作者:
Wang Y;Chen L;Li Q;Gao S;Liu S;Ma J;Xie Y;Wang J;Cao Z;Liu Z

文献摘要

参考文献

相似文献

肌醇多聚磷酸酶II(INPP4B)被认为是一种肿瘤抑制因子,但对其在多发性骨髓瘤(MM)中的表达和功能知之甚少。在本研究中,我们检测了28例初诊MM患者和42例髓外浆细胞瘤(EMP)患者与正常浆细胞相比INPP4B的表达,发现INPP4B的低表达与MM患者的预后不良相关。此外,INPP4B在7种MM细胞系中的表达均低于正常浆细胞。此外,INPP4B功能的丧失促进了MM细胞的增殖,但功能的增强抑制了MM细胞的增殖,使细胞周期停滞在G0/G1噬菌体。同时,INPP4B基因敲除增强了MM细胞的耐药性,但过度表达提高了MM细胞对Bortezomib治疗的敏感性。从机制上讲,我们发现INPP4B通过抑制Akt在赖氨酸473位的磷酸化来发挥作用,但不能抑制苏氨酸308位的磷酸化,从而减弱PI3K/Akt/哺乳动物雷帕霉素靶(MTOR)信号通路的激活。因此,我们确认了INPP4B在MM中的抑制作用,我们的发现提示INPP4B的表达缺失是侵袭性MM的一个危险因素。
Inositol polyphosphate-4-phosphatase type II (INPP4B) has been identified as a tumor suppressor, while little is known about its expression and function in multiple myeloma (MM). In this study, we evaluated the expression of INPP4B in 28 cases of newly diagnosed MM patients and 42 cases of extramedullary plasmacytoma (EMP) patients compared with normal plasma cells and found that low INPP4B expression was correlated with poor outcomes in MM patients. Moreover, expression of INPP4B in seven MM cell lines was all lower than that in normal plasma cells. In addition, loss of function of INPP4B promoted cell proliferation in MM cells; however, gain of function suppressed MM cells proliferation and arrested the cell cycle at G0/G1 phage. Meanwhile, knockdown of INPP4B enhanced resistance, but overexpression promoted sensitivity to bortezomib treatment in MM cells. Mechanistically, we found that INPP4B exerted its role via inhibiting the phosphorylation of Akt at lysine 473 but not threonine 308, which attenuated the activation of the PI3K/Akt/mammalian target of rapamycin (mTOR) signaling pathway. Therefore, we identified an inhibitory effect of INPP4B in MM, and our findings suggested that loss of INPP4B expression is a risk factor of aggressive MM.
靶向NSD2介导的SRC-3液-液相分离使硼替佐米治疗多发性骨髓瘤变得敏感
DOI: 10.1038/s41467-021-21386-y
发表时间: 2021-02-15
影响因子: 16.6
作者:
Liu J;Xie Y;Guo J;Li X;Wang J;Jiang H;Peng Z;Wang J;Wang S;Li Q;Ye L;Zhong Y;Zhang Q;Liu X;Lonard DM;Wang J;O'Malley BW;Liu Z
通讯作者: Liu Z
蛋白酶体抑制剂诱导 SIRT1 使 GLI2 去乙酰化,增强多发性骨髓瘤中的 hedgehog 信号活性和耐药性
DOI: 10.1038/s41388-019-1037-6
发表时间: 2020-01-01
期刊: ONCOGENE
影响因子: 8
作者:
Xie, Ying;Liu, Jing;Liu, Zhiqiang
通讯作者: Liu, Zhiqiang
DOI: 10.1016/j.bbrc.2017.02.012
发表时间: 2017-03-25
影响因子: 3.1
作者:
Croft, Amanda;Guo, Su Tang;Jiang, Chen Chen
通讯作者: Jiang, Chen Chen
在黑色素瘤的子集中,INPP4B 上调并通过 SGK3 发挥致癌驱动作用。
DOI: 10.18632/oncotarget.5359
发表时间: 2015-11-24
期刊: Oncotarget
影响因子: --
作者:
Chi MN;Guo ST;Wilmott JS;Guo XY;Yan XG;Wang CY;Liu XY;Jin L;Tseng HY;Liu T;Croft A;Hondermarck H;Scolyer RA;Jiang CC;Zhang XD
通讯作者: Zhang XD
DOI: 10.1182/blood-2014-09-603555
发表时间: 2015-04-30
期刊: BLOOD
影响因子: 20.3
作者:
Rijal, Sewa;Fleming, Shaun;Wei, Andrew H.
通讯作者: Wei, Andrew H.